Reply to ‘Malignant pericardial effusion: sclerotherapy or local chemotherapy?' by Kunitoh, H et al.
Letter to the Editor
Reply to ‘Malignant pericardial effusion: sclerotherapy or local
chemotherapy?’
H Kunitoh*,1, T Tamura
2 and N Saijo
3
1Department of Respiratory Medicine, Mitsui Memorial Hospital, 1 Kandaizumi-cho, Chiyoda-ku, Tokyo, Japan;
2Department of Medical Oncology,
National Cancer Center Hospital, Tokyo, Japan;
3Department of Medical Oncology, Kinki University School of Medicine, Osakasayama, Japan
British Journal of Cancer (2009) 101, 736–737. doi:10.1038/sj.bjc.6605223 www.bjcancer.com
& 2009 Cancer Research UK
                
Sir,
We agree with Lestuzzi et al (2009) that our results on treatment
using pericardial sclerosis with bleomycin in patients with lung
cancer-associated malignant pericardial effusion (MPE), which was
recently published in the British Journal of Cancer (Kunitoh et al,
2009), are unsatisfactory and leave much room for improvement.
Although the acute toxicity/morbidity of the procedure was low,
there were two cases with possible late pericardial constriction.
Moreover, although our data did show a definite tendency for
better control of MPE with pericardial sclerosis as compared with
drainage alone, the primary end point of the phase III trial,
survival without recurrent MPE at 2 months, was not statistically
met. Therefore, the therapeutic advantage seems modest.
Having said that, we would like to rebut the points raised by
Dr Lestuzzi et al on our paper.
First, they claim that the study subjects might not have had
MPE, as there were some patients with cytology-negative effusion.
It is well known that cytology is not always positive in MPE; in fact,
according to Press and Livingston (1987), effusion cytology was
positive in 151 (79%) of the 190 cases with pericardiocentesis-
diagnosed MPE. That positivity rate was similar to that of
our report, in which 57 (75%) of the cases examined for effusion
cytology had positive results. With moderate or massive
pericardial effusion clinically indicated for drainage in patients
with confirmed lung cancer, the clinical diagnosis of MPE should
be justified unless other findings suggest otherwise.
We do not rule out the possibility that there were a few cases
with non-malignant effusion, and we do recognise that even among
MPE patients cytology-positive cases should have larger tumour
burden and worse prognosis (Gornik et al, 2005). Therefore, we
performed a subset analysis (shown in Figures 2 and 3 of our
paper), which showed the superiority of pericardial sclerosis in
both cytology-positive and -negative cases. It would be clinically
unjustified to wait for the results of repeated cytology in the
management of clinically diagnosed MPE. We put priority on the
clinical management of these patients with dismal disease, and not
on the precision of biology or terminology.
On the second point, we agree with Dr Lestuzzi et al that
previous reports, including that of ours, do not differentiate
intrapericardial therapies according to the instilled agents, which
range from purely ‘sclerotic’ agents, such as tetracycline, to almost
purely chemotherapeutic agents, such as platinum. However, we
understand that many of the previous trials are those on
pericardial sclerosis and not on local chemotherapy; thiopeta,
vinblastine and bleomycin have minimal activity against advanced
lung cancers. Pericardial ‘local’ chemotherapy should be consi-
dered to be a relatively new strategy.
Finally, we must comment on Dr Lestuzzi et al’s claim regarding
the ‘local chemotherapy’ with intrapericardial platinum.
First, we do not believe that it would be realistic to expect or try
to ‘cure’ MPE in patients with far-advanced lung cancer. The aim
of the management should be good and lasting palliation.
Of course, as we stated above, our results leave much room to be
improved. Overall, the therapeutic advantage seems modest.
Although massive bleeding upon re-attempted drainage occurred
in two patients who did not take intrapericardial bleomycin, we
did observe two cases with late pericardial constriction on taking
bleomycin, which could be of more concern as improvement
of lung cancer treatment yields more long-term survivors. There
is certainly the possibility that intrapericardial platinum, as
Dr Lestuzzi et al claim, may bring additional benefits to the patients.
However, their data, as well as those of others in the medical
literature, are only from phase II trials or case series. In many
of the trials, they treated various tumours with various agents,
without any controlled data whatsoever. Their results could be
useful as hypothesis-generating findings, but establishment of a
standard therapy requires well-designed controlled trials.
We urge Dr Lestuzzi et al to conduct a phase III trial based on
their rationale for intrapericardial platinum. In fact, that exactly is
what we proposed as the next trial in the Discussion section. If they
remain unconvinced with our data, they could put drainage alone
for control. Phase III trials are much more difficult to conduct, but
that is the only way in which they can demonstrate the superiority
of their strategy.
In conclusion, we appreciate Dr Lestuzzi et al for their interest
in our paper and for their effort towards improving the manage-
ment of patients with MPE. However, phase II data cannot
substitute for a randomised controlled trial to make medical
evidence. They need to conduct a better phase III trial than ours
to validate their claim.
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